Search

Displaying results 1821 - 1830 of 8010 in total
  1. Drug

    Cefotiam

    go.drugbank.com/drugs/DB00229
    Approved

    One of the cephalosporins that has a broad spectrum of activity against both gram-positive and gram-negative microorganisms.

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use
  2. Drug

    Linvoseltamab

    go.drugbank.com/drugs/DB17447
    ApprovedInvestigational

    [L53353] It received conditional marketing authorization in the European Union in April 2025 for patients with three or more prior lines of therapy, [L53358] and was granted accelerated approval by the … FDA in July 2025 for patients who have undergone four or more prior lines. Continued approval in the U.S. is contingent upon verification of clinical benefit in a confirmatory trial. [L53363]

  3. Drug

    Demeclocycline

    go.drugbank.com/drugs/DB00618
    Approved

    Because it is excreted more slowly than tetracycline, it maintains effective blood levels for longer periods of time.

    Categories: Antibiotics for Topical Use, Antibacterials for Systemic Use
  4. Drug

    Lunsotogene parvec

    go.drugbank.com/drugs/DB18278
    ApprovedInvestigational

    Lunsotogene parvec is a first-in-class dual adeno-associated virus serotype 1 vector-based gene therapy developed to address an unmet medical need for OTOF-related sensorineural hearing loss. … [L56136] On April 23, 2026, the FDA granted accelerated approval for the treatment of pediatric and adult patients with severe-to-profound hearing loss associated with molecularly confirmed biallelic

  5. Drug

    Chlorothiazide

    go.drugbank.com/drugs/DB00880
    ApprovedInvestigationalVet approved

    (From Martindale, The Extra Pharmacopoeia, 30th ed, p812)

  6. Drug

    Tiludronic acid

    go.drugbank.com/drugs/DB01133
    ApprovedVet approvedWithdrawn

    [A1923] Tiludronic acid was first described in the literature in 1988 as a potential treatment for Paget's disease of bone.[A202235] Tiludronic acid was granted FDA approval on 7 March 1997.[L4763] … Tiludronate, or (4-chlorophenyl)thio-methylene-1,1-bisphosphonate, is a first generation bisphosphonate similar to [etidronic acid] and [clodronic acid].

    Categories: Drugs for Treatment of Bone Diseases
  7. Drug

    Pegunigalsidase alfa

    go.drugbank.com/drugs/DB14992
    ApprovedInvestigational

    [L46342,L46387] Later on, the FDA approved pegunigalsidase alfa for the treatment of adult patients with Fabry disease that same month.[L46432,L46437] … Pegunigalsidase alfa (PRX-102) is a recombinant form of human α-galactosidase-A indicated for long-term enzyme replacement therapy in patients with Fabry disease, a rare genetic disorder characterized

  8. Drug

    Cyclacillin

    go.drugbank.com/drugs/DB01000
    Approved

    A cyclohexylamido analog of penicillanic acid.

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use
  9. Drug

    Dequalinium

    go.drugbank.com/drugs/DB04209
    Approved

    Dequalinium is an antibacterial agent with multi-targeted actions. It also possesses antifungal, antiparasitic, antiviral, anticancer, and neuroprotective properties. It is a quaternary ammonium compound, as it consists of an amphipathic...

    Mixtures: Eucillin "B" - Salbe
  10. Drug

    Defactinib

    go.drugbank.com/drugs/DB12282
    ApprovedInvestigational

    [L53208,A273943] Defactinib was approved by the US FDA in May 2025 in a co-package alongside [avutometinib] (called Avmapki Fakzynja) for the treatment of recurrent KRAS-mutated low-grade serous ovarian … [L53198,L53208] FAK is important for the integrin-mediated activation of several downstream signal transduction pathways, including those involving RAS/MEK/ERK and PI3K/Akt, and its upregulation is a key